Denmark Pharmaceutical Market – Drug Development & Forecast 2026–2034

Denmark Pharmaceutical Market Size and Forecast 2026-2034

Denmark Pharmaceutical Market will grow from US$ 3.94 Billion in 2025 to US$ 5.38 Billion in 2034, at a Compound Annual Growth Rate (CAGR) of 3.52% from 2026–2034. Market growth is driven by increasing healthcare expenditure, strong government support for life sciences, rising prevalence of chronic diseases, and continuous innovation in drug development and biotechnology. Expansion of research and development activities, advanced healthcare infrastructure, and growing demand for personalized medicine further strengthen the market outlook. Additionally, Denmark’s strong pharmaceutical manufacturing base and export-oriented industry contribute significantly to long-term growth.

Denmark Pharmaceutical Market Overview

Pharmaceuticals refer to drugs and medicinal products used for the prevention, diagnosis, treatment, and management of diseases and health conditions in humans and animals. They include prescription medicines, over-the-counter drugs, vaccines, biologics, and advanced therapies developed through chemical synthesis or biotechnology. Pharmaceuticals play a vital role in improving public health, increasing life expectancy, and enhancing quality of life by controlling infections, chronic diseases, and acute medical conditions.

In Denmark, pharmaceuticals are highly important due to the country’s strong healthcare system, advanced research infrastructure, and high level of public health awareness. The Danish population benefits from universal healthcare access, which ensures widespread use of medicines for conditions such as diabetes, cardiovascular diseases, cancer, and respiratory disorders. The country is also a global leader in pharmaceutical innovation, with strong companies and research institutions focusing on biotechnology and drug development. Rising investment in personalized medicine and biologics further supports market growth. Additionally, Denmark’s export-oriented pharmaceutical industry contributes significantly to the national economy. The combination of innovation, healthcare accessibility, and strong regulatory standards makes pharmaceuticals highly popular and essential in Denmark’s modern healthcare landscape.

Pharmaceutical Drug Launches in Denmark

Date	Drug / Brand	Company	Therapeutic Area	Description
2025	Lynkuet (elinzanetant)	Bayer	Menopause symptoms	Approved in EU, launched across European markets including Denmark
2024	Rystiggo (rozanolixizumab)	UCB	Neurology (myasthenia gravis)	Approved in EU and launched for rare autoimmune disease treatment
2024	Tevimbra (tislelizumab)	BeiGene	Oncology	New PD-1 immunotherapy launched in European markets
2024	Mounjaro (tirzepatide)	Eli Lilly	Diabetes/Obesity	Launched in Denmark competing with Wegovy
2023	Wegovy expansion	Novo Nordisk	Obesity	Expanded availability and high-demand rollout in Denmark
2024	Ozempic expanded use controls	Novo Nordisk	Diabetes	Continued regulated expansion and prescribing updates in Denmark
2024	Orforglipron (GLP-1 pipeline rollout updates)	Eli Lilly	Diabetes	Early European regulatory pathway advancement
2023	Concizumab (Alhemo)	Novo Nordisk	Hemophilia	EU-authorized prophylaxis treatment for bleeding disorders
2023	Biosimilar insulin products expansion	Multiple	Diabetes	Increased generics and biosimilar insulin availability in Denmark
2024	Rare disease biologics expansion	Multiple EU pharma firms	Rare diseases	Increased approvals of biologic therapies across Denmark via EMA system

Number of adults (20–79 years) with diabetes in Denmark

Years	Thousands
2000	561.7
2011	299.5
2024	354.7
2050	375.8

Growth Drivers of the Denmark Pharmaceutical Market

Strong Healthcare System and Government Support

Denmark’s pharmaceutical market is strongly supported by its universal healthcare system and government-backed healthcare policies. The country ensures equal access to medicines and advanced treatments for all citizens, which significantly drives pharmaceutical consumption. Public healthcare funding covers a large portion of prescription drug costs, encouraging higher usage of innovative and essential medicines. The Danish government also invests heavily in healthcare infrastructure, digital health systems, and medical research, creating a strong ecosystem for pharmaceutical growth. Regulatory authorities maintain high-quality standards, which enhances trust in medicines and encourages innovation. Additionally, national healthcare programs focusing on chronic disease management, elderly care, and preventive healthcare further increase demand for pharmaceuticals. Denmark’s emphasis on efficiency, early diagnosis, and modern treatment approaches ensures continuous adoption of advanced drugs. As healthcare needs grow with an aging population, government support remains a key driver supporting long-term expansion of the pharmaceutical industry in Denmark.

Rising Biopharmaceutical Innovation and R&D Activities

Denmark is one of Europe’s leading hubs for pharmaceutical innovation, particularly in biotechnology and biopharmaceutical research. Strong collaboration between universities, research institutes, and global pharmaceutical companies has created a highly innovative environment. Companies in Denmark focus heavily on developing biologics, vaccines, insulin therapies, and personalized medicines. The presence of world-class research infrastructure and skilled scientific talent supports continuous drug discovery and clinical trials. Government incentives and funding programs encourage innovation in life sciences, making Denmark attractive for global pharmaceutical investments. Increasing demand for advanced treatments for chronic diseases such as diabetes, cancer, and cardiovascular conditions is further driving research activities. The country’s export-oriented pharmaceutical industry also motivates companies to develop high-value, innovative drugs for international markets. As biopharmaceutical technologies evolve, Denmark continues to strengthen its position as a global leader in pharmaceutical innovation, significantly boosting market growth.

Growing Prevalence of Chronic Diseases and Aging Population

The increasing prevalence of chronic diseases and the aging population are major growth drivers for the Denmark pharmaceutical market. Conditions such as diabetes, cardiovascular diseases, obesity, cancer, and respiratory disorders are becoming more common due to lifestyle changes and demographic shifts. Denmark’s elderly population is expanding, leading to higher demand for long-term medication, specialized treatments, and continuous healthcare management. Chronic disease management requires regular pharmaceutical intervention, which significantly increases drug consumption across the country. Additionally, rising awareness about preventive healthcare and early diagnosis is contributing to higher medicine usage. Healthcare providers are focusing on long-term treatment plans, increasing dependency on prescription drugs and advanced therapies. The growing need for effective and innovative medicines to improve quality of life in aging populations further supports pharmaceutical market growth. This demographic shift ensures sustained demand for both generic and advanced pharmaceutical products in Denmark.

Challenges of the Denmark Pharmaceutical Market

High Cost of Drug Development and Regulatory Pressure

One of the major challenges in the Denmark pharmaceutical market is the high cost associated with drug development and strict regulatory requirements. Developing new pharmaceuticals, especially biologics and innovative therapies, requires significant investment in research, clinical trials, and regulatory approvals. Denmark follows stringent European Union pharmaceutical regulations that ensure drug safety and efficacy but also increase the time and cost required for product approvals. Smaller companies often face difficulties in meeting these requirements due to limited financial and technical resources. Additionally, compliance with evolving environmental and safety standards adds further operational costs. The long development cycle of new medicines delays market entry and revenue generation for pharmaceutical firms. Pricing pressures from government healthcare systems and reimbursement policies also limit profit margins. As a result, companies must balance innovation with cost efficiency while navigating complex regulatory frameworks, making drug development a capital-intensive and highly competitive process in Denmark.

Dependence on Export Markets and Global Competition

Denmark’s pharmaceutical industry is highly export-oriented, making it vulnerable to global market fluctuations and intense international competition. A large share of pharmaceutical production is exported to Europe, North America, and other global markets, meaning demand is influenced by external economic conditions, trade policies, and regulatory changes in foreign countries. Competition from large multinational pharmaceutical companies and low-cost generic manufacturers puts pressure on Danish firms to continuously innovate and maintain high-quality standards. Currency fluctuations and international pricing regulations can also impact profitability and revenue stability. Additionally, supply chain disruptions, geopolitical uncertainties, and trade barriers may affect the smooth export of pharmaceutical products. Dependence on external markets makes the industry sensitive to global economic downturns. To remain competitive, Danish pharmaceutical companies must invest heavily in innovation, efficiency, and diversification of export destinations while managing risks associated with global market dependency.

Denmark Cancer Pharmaceutical Market

The Denmark Cancer Pharmaceutical Market is a rapidly growing segment driven by increasing cancer incidence and strong demand for advanced oncology treatments. Cancer remains one of the leading health concerns in Denmark, with rising cases of breast, lung, prostate, and colorectal cancers. The market benefits from the country’s advanced healthcare infrastructure, early diagnosis programs, and strong government support for oncology care. Pharmaceutical companies are focusing on developing targeted therapies, immunotherapies, and biologics that offer higher treatment effectiveness and fewer side effects compared to traditional chemotherapy. Denmark’s strong research ecosystem, including collaborations between hospitals, universities, and global pharmaceutical firms, supports continuous innovation in cancer drug development. Additionally, increasing investments in personalized medicine and precision oncology are improving treatment outcomes. The availability of reimbursement policies under the public healthcare system further enhances patient access to expensive cancer therapies. As awareness and screening programs expand, demand for innovative cancer pharmaceuticals is expected to grow steadily across Denmark.

Denmark Diabetes Pharmaceutical Market

The Denmark Diabetes Pharmaceutical Market is expanding significantly due to the rising prevalence of diabetes, particularly type 2 diabetes linked to lifestyle changes, obesity, and aging population. Diabetes management in Denmark relies heavily on pharmaceutical interventions, including insulin, oral antidiabetic drugs, and advanced biologic therapies. The country has a strong healthcare system that ensures early diagnosis and continuous treatment, supporting consistent demand for diabetes medications. Pharmaceutical companies are increasingly focusing on developing long-acting insulin, GLP-1 receptor agonists, and combination therapies that improve patient compliance and glucose control. Denmark is also a leader in diabetes research, with several global pharmaceutical firms conducting clinical trials in the country. Government healthcare reimbursement policies make diabetes medications widely accessible, encouraging long-term treatment adherence. Growing awareness of preventive healthcare and lifestyle management further supports market expansion. As diabetes cases continue to rise, the demand for innovative, effective, and affordable pharmaceutical solutions remains strong in Denmark.

Denmark Generic Pharmaceutical Market

The Denmark Generic Pharmaceutical Market plays an essential role in reducing healthcare costs while ensuring widespread access to essential medicines. Generic drugs are widely used in Denmark due to strong government support for cost-effective healthcare solutions under the public health system. These medications offer the same safety, quality, and efficacy as branded drugs but at significantly lower prices, making them highly attractive for both patients and healthcare providers. The market is driven by increasing patent expirations of branded drugs and rising demand for affordable treatment options for chronic diseases such as cardiovascular disorders, diabetes, and infections. Pharmaceutical companies in Denmark and across Europe are actively expanding their generic drug portfolios to meet growing demand. Strict regulatory standards ensure high-quality production and patient safety, enhancing trust in generic medicines. Additionally, hospital procurement systems and public tenders strongly favor generics, further boosting market adoption. The growing focus on healthcare cost optimization continues to drive steady expansion of the generic pharmaceutical market in Denmark.

Denmark Pharmaceutical Hospital Pharmacy Market

The Denmark Pharmaceutical Hospital Pharmacy Market is a vital part of the healthcare system, ensuring efficient distribution and administration of medicines within hospitals and clinical settings. Hospital pharmacies in Denmark manage a wide range of pharmaceuticals, including oncology drugs, antibiotics, anesthetics, biologics, and emergency medicines. The market is driven by increasing hospital admissions, rising prevalence of chronic diseases, and growing demand for specialized treatments requiring hospital-based care. Denmark’s advanced healthcare infrastructure supports integrated hospital pharmacy systems that ensure accurate medication dispensing, patient safety, and effective treatment outcomes. The adoption of digital health technologies and automated pharmacy management systems has further improved efficiency and reduced medication errors. Hospital pharmacies also play a key role in clinical trials and research collaborations with pharmaceutical companies, supporting drug development and innovation. Government funding and centralized procurement systems ensure availability of essential medicines across hospitals. As healthcare services expand and treatment complexity increases, the hospital pharmacy pharmaceutical market in Denmark continues to grow steadily.

Research Methodology of the Denmark Pharmaceutical Market

Step 1: Market Definition and Scope

The market was first defined by establishing the scope of pharmaceutical products sold and distributed within Denmark included in the analysis. The assessment covered the value of human-use pharmaceutical products sold through retail pharmacies, hospital channels, and other applicable pharmaceutical distribution channels.

The market assessment considered prescription and over-the-counter (OTC) medicines, with segmentation based on therapeutic category, drug type, formulation, route of administration, and distribution channel. Similar market definitions used by industry research distinguish human-use prescription and OTC medicines from medical devices, diagnostics, supplements, and veterinary medicines.

The assessment considered:

• Prescription drugs
• Branded drugs
• Generic drugs
• OTC drugs
• Innovative drugs
• Specialty pharmaceuticals
• Hospital pharmaceuticals
• Retail pharmaceuticals
• Selected pharmaceutical products distributed through online channels

The market excluded:

• Medical devices
• Diagnostics
• Dietary supplements
• Cosmetics
• Veterinary medicines
• Pharmaceutical manufacturing equipment
• Healthcare services
• Hospital infrastructure

Where applicable, revenues were measured at the manufacturer or market value level, with adjustments made to maintain consistency across retail, hospital, and other distribution channels.

Step 2: Bottom-Up Approach

The bottom-up approach was used as a primary method for estimating the Denmark Pharmaceutical Market.

The calculation began with pharmaceutical sales volumes and values across major therapeutic categories, drug types, and distribution channels. The estimated sales volume was multiplied by the applicable average selling price to derive the market value.

The basic formula used was:

Pharmaceutical Market = Pharmaceutical Volume × Average Selling Price

Where reliable sales-value information was directly available, reported pharmaceutical sales were used instead of estimating revenue from volume and price.

The calculation was performed separately across different pharmaceutical categories because drug prices, prescription patterns, treatment volumes, reimbursement mechanisms, and product mixes vary substantially between therapeutic areas.

The analysis considered:

• Oncology
• Cardiovascular diseases
• Diabetes
• Respiratory diseases
• Infectious diseases
• Central nervous system disorders
• Autoimmune diseases
• Gastrointestinal diseases
• Other therapeutic categories

Official Danish pharmaceutical statistics provide information on medicine sales, quantities sold, and the number of people receiving treatment, providing an important basis for the bottom-up estimation.

Step 3: Pharmaceutical Sales and Average Price Estimation

Pharmaceutical sales volumes were estimated using official medicine-sales databases, pharmaceutical-company disclosures, industry associations, regulatory data, distributor information, and primary research.

The average selling price was estimated separately for major drug categories.

The calculation was expressed as:

Average Selling Price = Pharmaceutical Sales Value ÷ Pharmaceutical Units Sold

The assessment considered differences in:

• Branded versus generic medicines
• Prescription versus OTC medicines
• Innovative versus mature products
• Specialty medicines
• Hospital versus retail products
• Dosage form
• Strength
• Pack size
• Therapeutic category
• Reimbursement status
• Patent status
• Generic substitution
• Pricing changes

Denmark's pharmaceutical pricing environment was specifically incorporated into the model. Prescription-only and pharmacy-only OTC medicines are subject to a common pharmacy price, with companies reporting price changes at 14-day intervals; the lowest-price medicine can subsequently receive the right to be offered at pharmacies.

Step 4: Therapeutic-Class Market Calculation

The pharmaceutical market was calculated separately across major therapeutic categories.

Oncology Market

Cancer Drug Volume × Oncology Drug ASP

Diabetes Market

Diabetes Drug Volume × Diabetes Drug ASP

Cardiovascular Market

Cardiovascular Drug Volume × Cardiovascular Drug ASP

Respiratory Market

Respiratory Drug Volume × Respiratory Drug ASP

Infectious Disease Market

Infectious Disease Drug Volume × Infectious Disease Drug ASP

Central Nervous System Market

CNS Drug Volume × CNS Drug ASP

Autoimmune Disease Market

Autoimmune Drug Volume × Autoimmune Drug ASP

The overall market was subsequently calculated as:

Total Pharmaceutical Market = Oncology + Cardiovascular + Diabetes + Respiratory + Infectious Diseases + CNS + Autoimmune + Other Therapeutic Categories

Where products could fall into multiple therapeutic classifications, the classification system used by the underlying pharmaceutical database was maintained to avoid double counting.

Step 5: Drug-Type Estimation

The market was further segmented according to pharmaceutical product type.

The analysis considered:

• Prescription drugs
• OTC drugs
• Branded drugs
• Generic drugs
• Innovative medicines
• Specialty pharmaceuticals

For each category, the analysis identified:

• Sales value
• Sales volume
• Number of products
• Average price
• Prescription volume
• Generic penetration
• Patent status
• Market share
• Reimbursement status
• Distribution channel

The market value for each drug category was calculated separately and aggregated to determine the total Denmark Pharmaceutical Market.

The distinction between prescription and OTC medicines is particularly important because official Danish prescription statistics do not cover all OTC purchases, nor medicines administered in hospitals or used in general practice.

Step 6: Distribution-Channel Estimation

The bottom-up calculation was further performed across major pharmaceutical distribution channels.

The analysis considered:

• Retail pharmacies
• Hospital pharmacies
• Hospitals
• Online pharmacies
• Other authorized pharmaceutical channels

For each channel, the analysis identified:

• Pharmaceutical sales
• Prescription volumes
• Drug categories
• Average prices
• Reimbursement levels
• Procurement patterns
• Hospital tender activity
• Generic substitution
• Distribution margins

The channel-level estimates were aggregated to determine the total pharmaceutical market.

Official Danish data provide detailed information on pharmaceutical purchases and can be used to distinguish prescription-related purchases and other pharmaceutical consumption patterns.

Step 7: Top-Down Validation

Following the bottom-up estimation, a top-down validation was conducted using national pharmaceutical expenditure, healthcare expenditure, pharmaceutical-industry revenue, and company-level financial information.

The analysis considered:

• Total pharmaceutical expenditure
• Prescription pharmaceutical expenditure
• OTC pharmaceutical expenditure
• Hospital pharmaceutical expenditure
• Retail pharmaceutical expenditure
• Pharmaceutical imports
• Pharmaceutical exports
• Pharmaceutical manufacturer revenue
• Healthcare expenditure
• Pharmaceutical-company sales

Company and industry revenue was adjusted to remove activities outside the defined Denmark pharmaceutical market, including:

• International pharmaceutical sales
• Contract manufacturing for overseas markets
• Medical devices
• Diagnostics
• Animal health
• Consumer healthcare products outside the defined scope
• Non-pharmaceutical services

This was particularly important because Denmark has a large pharmaceutical manufacturing and export industry, meaning domestic pharmaceutical consumption should not be confused with pharmaceutical manufacturing revenue generated in Denmark.

Step 8: Pharmaceutical Consumption and Prescription Validation

The estimated market was further validated against pharmaceutical consumption and prescription data.

The assessment considered:

• Number of people receiving treatment
• Number of prescriptions redeemed
• Prescriptions per person
• Pharmaceutical units sold
• Treatment prevalence
• Therapeutic-category consumption
• Age-related medicine consumption
• Geographic distribution
• Disease prevalence

Statistics Denmark's prescription-drug statistics are based on pharmaceutical sales data supplied through the Danish Health Data Agency and can be analyzed according to medicine type, age, gender, geography, and other population characteristics.

The relationship between prescription volumes, treatment population, pharmaceutical units, and market value was examined to validate the revenue-based market estimate.

Step 9: Third Validation and Market Triangulation

A third validation layer was conducted through market triangulation. Three independent estimation perspectives were compared:

A. Sales-Based Approach

Pharmaceutical Sales Volume × Average Pharmaceutical Price

B. Expenditure-Based Approach

Total Pharmaceutical Expenditure × Applicable Market Share

C. Company and Product-Based Approach

Pharmaceutical Sales of Major Companies + Estimated Sales of Other Market Participants

The three estimates were compared to identify significant differences.

Where discrepancies occurred, the underlying assumptions were investigated, including:

• Differences in market definitions
• Retail versus hospital sales
• Prescription versus OTC coverage
• Domestic sales versus manufacturing revenue
• Manufacturer versus retail prices
• VAT treatment
• Generic substitution
• Pharmaceutical reimbursement
• Hospital procurement
• Product launches
• Patent expirations
• Currency conversion
• International versus domestic revenue

The final market estimate was established after reconciling these differences and assessing the reliability and coverage of the underlying data.

Step 10: Company-Level Validation

Major pharmaceutical manufacturers, biotechnology companies, distributors, wholesalers, pharmacies, hospital procurement organizations, and healthcare stakeholders were analyzed as part of the validation process.

The assessment considered:

• Denmark pharmaceutical revenue
• Product sales
• Market share
• Product launches
• Patent expirations
• Generic competition
• R&D expenditure
• Clinical development
• Manufacturing capacity
• Distribution networks
• Hospital contracts
• Pharmaceutical pipeline
• Therapeutic-area exposure

Major companies with significant exposure to the Danish pharmaceutical ecosystem were analyzed using their annual reports, financial statements, investor presentations, product information, and other publicly available disclosures.

Where companies separately reported Denmark-specific pharmaceutical sales, the reported figures were incorporated into the validation process.

Where Denmark-specific revenue was unavailable, the relevant contribution was estimated using product sales, Nordic/European revenue disclosures, market share information, distribution data, and primary research.

Step 11: Primary Research Validation

Primary research was conducted with participants across the Danish pharmaceutical ecosystem, including:

• Pharmaceutical manufacturers
• Biotechnology companies
• Distributors
• Wholesalers
• Pharmacists
• Hospital procurement managers
• Healthcare professionals
• Pharmaceutical sales representatives
• Regulatory specialists
• Healthcare consultants
• Key opinion leaders

Respondents were consulted regarding:

• Pharmaceutical demand
• Prescription trends
• Pricing
• Generic penetration
• Reimbursement
• Hospital procurement
• Product launches
• Patent expirations
• Therapeutic-category growth
• Distribution trends
• Pharmaceutical innovation
• Competitive dynamics
• Future market developments

Primary research findings were compared with official pharmaceutical sales statistics and company-level information. Where significant differences were identified, the relevant assumptions were reviewed and adjusted.

Step 12: Market Forecasting

The Denmark Pharmaceutical Market was forecast by estimating future pharmaceutical consumption, treatment population, product prices, therapeutic-category growth, and changes in the pharmaceutical product mix.

The primary forecast formula was:

Future Pharmaceutical Market Size = Forecast Pharmaceutical Volume × Forecast Average Selling Price

The forecast incorporated major demand and supply factors, including:

• Aging population
• Increasing prevalence of chronic diseases
• Oncology treatment demand
• Diabetes prevalence
• Cardiovascular disease
• Respiratory diseases
• Specialty medicines
• Biologics
• Biosimilars
• Generic medicines
• Pharmaceutical innovation
• New drug launches
• Patent expirations
• Generic substitution
• Healthcare expenditure
• Pharmaceutical pricing
• Reimbursement policies
• Hospital pharmaceutical procurement
• R&D activity
• Government healthcare policies

The forecast was developed separately for major therapeutic categories, drug types, and distribution channels rather than applying a single growth rate to the entire pharmaceutical market.

This approach allows the model to capture differences between high-growth specialty medicines, mature generic products, OTC medicines, and hospital pharmaceuticals.

Overall Market Estimation Framework

The methodology can therefore be summarized as:

Market Definition & Scope
↓
Pharmaceutical Sales Data Collection
↓
Volume & Price Analysis
↓
Therapeutic-Class Estimation
↓
Prescription / OTC Analysis
↓
Distribution-Channel Estimation
↓
Company-Level Analysis
↓
Pharmaceutical Consumption Validation
↓
Top-Down Expenditure Validation
↓
Market Triangulation
↓
Historical Market Size
↓
Forecast Volume + Forecast ASP
↓
Denmark Pharmaceutical Market Forecast

This methodology provides a structured framework for estimating the historical and forecast value of the Denmark Pharmaceutical Market, while accounting for pharmaceutical sales, treatment volumes, pricing, therapeutic categories, prescription and OTC medicines, distribution channels, generic substitution, reimbursement, company-level performance, and changes in the Danish healthcare and pharmaceutical ecosystem.

Important methodological distinction: official Danish pharmaceutical-sales data are particularly valuable for domestic market sizing, but they should not be equated directly with pharmaceutical manufacturing revenue. The Danish Health Data Authority maintains a pharmaceutical-sales register covering medicine sales in Denmark, while Statistics Denmark's prescription statistics specifically cover prescription-related human-medicine sales. This distinction helps prevent the substantial Danish pharmaceutical export business from being inadvertently included in a domestic Denmark Pharmaceutical Market estimate.

Denmark Pharmaceutical Market Segments:

Therapeutic Class

• Cancer
• Infectious Diseases
• Cardiovascular Diseases
• Diabetes
• Respiratory Diseases
• Central Nervous System Disorders
• Autoimmune Diseases
• Others

Drug Type

• Branded
• Generic

Prescription Type

• OTC Drugs
• Prescription Drugs

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Cities

• Copenhagen
• Aarhus
• Odense
• Aalborg
• Esbjerg
• Randers
• Kolding
• Horsens
• Vejle
• Roskilde

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Novo Nordisk A/S
• H. Lundbeck A/S
• Leo Pharma A/S
• Orifarm Group A/S
• ALK-Abell A/S
• Xellia ApS
• Takeda Pharma A/S
• Sandoz A/S
• Ferring Pharmaceuticals A/S
• FUJIFILM Diosynth Biotechnologies

Report Details: